Corcept Therapeutics Incorporated (CORT) wird mit einem nachlaufenden KGV von gehandelt 44.4, erwartetes KGV von 116.2. Die nachlaufende Gewinnrendite beträgt 2.25%, erwartete Gewinnrendite 0.86%. PEG 0.99 (Peter Lynch unterbewertet ≤1,0). Die Graham-Zahl beträgt $11.57.
Durch diese Seite bewiesene Kriterien:
SharesGrow Gesamtbewertung: 77/100 mit 5/7 Kriterien bestanden.
| Year | P/E (TTM) | PEG-Verhältnis | P/B-Verhältnis | P/S-Verhältnis | Dividendenrendite |
|---|---|---|---|---|---|
| 2016 | 98.6 | -0.46 | 19.40 | 9.87 | - |
| 2017 | 15.9 | 0.01 | 10.74 | 12.88 | - |
| 2018 | 22.3 | -0.47 | 6.09 | 6.68 | - |
| 2019 | 14.7 | 0.40 | 3.73 | 4.51 | - |
| 2020 | 28.5 | 2.34 | 5.77 | 8.53 | - |
| 2021 | 20.4 | 3.74 | 6.09 | 6.26 | - |
| 2022 | 21.4 | -10.37 | 4.32 | 5.40 | - |
| 2023 | 31.7 | 4.30 | 6.64 | 6.97 | - |
| 2024 | 37.2 | 1.15 | 7.65 | 7.71 | - |
| 2025 | 36.3 | -1.22 | 5.58 | 4.75 | - |
| Year | EPS (verwässert) | Umsatz | Nettogewinn | Nettomarge |
|---|---|---|---|---|
| 2016 | $0.07 | $81.32M | $8.14M | 10% |
| 2017 | $1.04 | $159.2M | $129.12M | 81.1% |
| 2018 | $0.60 | $251.25M | $75.41M | 30% |
| 2019 | $0.77 | $306.49M | $94.18M | 30.7% |
| 2020 | $0.85 | $353.87M | $106.01M | 30% |
| 2021 | $0.89 | $365.98M | $112.51M | 30.7% |
| 2022 | $0.87 | $401.86M | $101.42M | 25.2% |
| 2023 | $0.94 | $482.38M | $106.14M | 22% |
| 2024 | $1.23 | $675.04M | $139.73M | 20.7% |
| 2025 | $0.82 | $761.41M | $99.65M | 13.1% |
| Year | EPS (Durchschn.) | EPS-Spanne | Umsatz (Durchschn.) | Umsatzspanne | Analysten |
|---|---|---|---|---|---|
| 2026 | $0.38 | $0.31 – $0.44 | $899.55M | $887.66M – $913.95M | 4 |
| 2027 | $1.30 | $0.32 – $1.86 | $1.09B | $1.06B – $1.16B | 4 |
| 2028 | $2.89 | $2.15 – $4.09 | $1.53B | $1.48B – $1.57B | 3 |
| 2029 | $6.13 | $5.56 – $6.90 | $2.12B | $1.97B – $2.33B | 1 |
| 2030 | $8.40 | $7.62 – $9.46 | $2.56B | $2.38B – $2.81B | 1 |
